Literature DB >> 25802400

The impact of rheumatoid arthritis on work capacity in Chinese patients: a cross-sectional study.

Xiaoying Zhang1, Rong Mu1, Xiuru Wang2, Chuanhui Xu1, Tianjiao Duan3, Yuan An1, Shuling Han2, Xiaofeng Li4, Lizhi Wang4, Caihong Wang4, Yongfu Wang5, Rong Yang5, Guochun Wang6, Xin Lu6, Ping Zhu7, Lina Chen7, Jinting Liu8, Hongtao Jin8, Xiangyuan Liu9, Lin Sun9, Ping Wei10, Junxiang Wang10, Haiying Chen10, Liufu Cui11, Rong Shu11, Bailu Liu11, Zhuoli Zhang12, Guangtao Li12, Zhenbin Li13, Jing Yang13, Junfang Li14, Bin Jia14, Fengxiao Zhang15, Jiemei Tao15, Jinying Lin16, Meiqiu Wei16, Xiaomin Liu17, Dan Ke17, Shaoxian Hu18, Cong Ye18, Xiuyan Yang19, Hao Li19, Cibo Huang20, Ming Gao20, Pei Lai20, Xingfu Li21, Lijun Song21, Yi Wang22, Xiaoyuan Wang22, Yin Su1, Zhanguo Li23.   

Abstract

OBJECTIVE: To evaluate the impact of RA on work capacity and identify factors related to work capacity impairment in patients with RA.
METHODS: A cross-sectional multicentre study was performed in 21 tertiary care hospitals across China. A consecutive sample of 846 patients with RA was recruited, of which 589 patients of working age at disease onset constituted the study population. Information on the socio-demographic, clinical, working and financial conditions of the patients was collected. Logistic regression analyses were used to identify factors associated with work capacity impairment.
RESULTS: The rate of work capacity impairment was 48.0% in RA patients with a mean disease duration of 60 months (interquartile range 14-134 months), including 11.7% leaving the labour force early, 33.6% working reduced hours and 2.7% changing job. Multivariable logistic regression analysis showed that reduced working hours was significantly related to current smoking [odds ratio (OR) 2.07 (95% CI 1.08, 3.97)], no insurance [OR 1.94 (95% CI 1.20, 3.12)], in manual labour [OR 2.66 (95% CI 1.68, 4.20)] and higher HAQ score [OR 2.22 (95% CI 1.36, 3.60)]. There was an association of current smoking [OR 3.75 (95% CI 1.54, 9.15)], in manual labour [OR 2.33 (95% CI 1.17, 4.64)], longer disease duration [OR 1.01 (95% CI 1.00, 1.01)] and lower BMI [OR 0.90 (95% CI 0.82, 0.99)] with leaving the labour force early.
CONCLUSION: There is a substantial impact of RA on the work capacity of patients in China. Social-demographic, disease- and work-related factors are all associated with work capacity impairment.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  cross-sectional study; rheumatoid arthritis; work capacity

Mesh:

Year:  2015        PMID: 25802400     DOI: 10.1093/rheumatology/kev014

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  5 in total

1.  Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China.

Authors:  SiNi Li; JianHe Li; LiuBao Peng; YaMin Li; XiaoMin Wan
Journal:  Rheumatol Ther       Date:  2021-04-24

Review 2.  A Systematic Review about the Efficacy and Safety of Tripterygium wilfordii Hook.f. Preparations Used for the Management of Rheumatoid Arthritis.

Authors:  Jing Wang; Na Chen; Liang Fang; Zhe Feng; Guochun Li; Attilio Mucelli; Xu Zhang; Xueping Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-08       Impact factor: 2.629

3.  Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.

Authors:  Zhanguo Li; Yuan An; Houheng Su; Xiangpei Li; Jianhua Xu; Yi Zheng; Guiye Li; Kenneth Kwok; Lisy Wang; Qizhe Wu
Journal:  Int J Rheum Dis       Date:  2018-01-04       Impact factor: 2.454

4.  The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.

Authors:  Yuan An; Tian Liu; Dongyi He; Lijun Wu; Juan Li; Yi Liu; Liqi Bi; Bin Zhou; Changsong Lin; Lan He; Xiangyuan Liu; Xiaofeng Li; Niansheng Yang; Zhuoli Zhang; Hui Song; Wei Wei; Jing Liu; Yu Bi; Zhanguo Li
Journal:  Clin Rheumatol       Date:  2016-10-05       Impact factor: 2.980

5.  Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.

Authors:  Zhan-Guo Li; Yi Liu; Hu-Ji Xu; Zhi-Wei Chen; Chun-De Bao; Jie-Ruo Gu; Dong-Bao Zhao; Yuan An; Lie-Ju Hwang; Lisy Wang; Joel Kremer; Qi-Zhe Wu
Journal:  Chin Med J (Engl)       Date:  2018-11-20       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.